BMO Capital Markets set a $44.00 price objective on Audentes Therapeutics (NASDAQ:BOLD) in a report published on Friday morning. The firm currently has a buy rating on the biotechnology company’s stock.
A number of other research firms have also weighed in on BOLD. William Blair reiterated a buy rating on shares of Audentes Therapeutics in a research report on Friday. HC Wainwright set a $37.00 price target on shares of Audentes Therapeutics and gave the stock a buy rating in a research report on Thursday. Wedbush upped their price target on shares of Audentes Therapeutics to $56.00 and gave the stock an outperform rating in a research report on Thursday. BidaskClub upgraded shares of Audentes Therapeutics from a buy rating to a strong-buy rating in a research report on Wednesday, December 20th. Finally, ValuEngine downgraded shares of Audentes Therapeutics from a hold rating to a sell rating in a report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Buy and an average target price of $35.00.
Audentes Therapeutics (NASDAQ:BOLD) traded down $4.19 on Friday, hitting $36.63. 665,400 shares of the company’s stock were exchanged, compared to its average volume of 935,925. The company has a market capitalization of $1,090.00 and a price-to-earnings ratio of -10.53. Audentes Therapeutics has a fifty-two week low of $13.90 and a fifty-two week high of $41.80.
Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.88). analysts forecast that Audentes Therapeutics will post -3.5 earnings per share for the current fiscal year.
In other news, Director Louis G. Lange sold 18,000 shares of the business’s stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $30.88, for a total value of $555,840.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Mary Newman sold 10,000 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $26.84, for a total transaction of $268,400.00. The disclosure for this sale can be found here. Insiders sold 36,000 shares of company stock worth $1,052,480 in the last three months. Insiders own 47.30% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the stock. Redmile Group LLC raised its stake in Audentes Therapeutics by 77.8% during the second quarter. Redmile Group LLC now owns 1,459,616 shares of the biotechnology company’s stock valued at $27,922,000 after purchasing an additional 638,780 shares in the last quarter. Perceptive Advisors LLC raised its stake in Audentes Therapeutics by 10.4% during the third quarter. Perceptive Advisors LLC now owns 781,309 shares of the biotechnology company’s stock valued at $21,885,000 after purchasing an additional 73,809 shares in the last quarter. Vanguard Group Inc. raised its stake in Audentes Therapeutics by 130.3% during the second quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock valued at $12,978,000 after purchasing an additional 383,837 shares in the last quarter. Alliancebernstein L.P. raised its stake in Audentes Therapeutics by 31.5% during the second quarter. Alliancebernstein L.P. now owns 640,654 shares of the biotechnology company’s stock valued at $12,256,000 after purchasing an additional 153,617 shares in the last quarter. Finally, State Street Corp raised its stake in Audentes Therapeutics by 231.6% during the second quarter. State Street Corp now owns 221,276 shares of the biotechnology company’s stock valued at $4,234,000 after purchasing an additional 154,544 shares in the last quarter. 78.95% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Audentes Therapeutics (BOLD) Given a $44.00 Price Target at BMO Capital Markets” was first reported by Equities Focus and is the sole property of of Equities Focus. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.equitiesfocus.com/2018/01/08/audentes-therapeutics-bold-given-a-44-00-price-target-at-bmo-capital-markets.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.